Market Size of Global Intravenous Solutions Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.30 % |
| Fastest Growing Market | North America |
| Largest Market | Asia Pacific |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Intravenous Solutions Market Analysis
The intravenous solutions market is projected to record a CAGR of nearly 4.3% over the forecast period (2022-2027).
The intravenous solutions market was significantly impacted by the COVID-19 outbreak. With the sudden outbreak, the demand for IV solutions grew worldwide to provide essential nutrients to patients in the intensive care unit (ICU). COVID-19 positively impacted the studied market as most pharmaceutical, biotechnology, and research institutes have been focusing on developing IV-based treatments against COVID-19. Moreover, with the easing of lockdown restrictions and the introduction of vaccines, the research and development activities are accelerating, thus boosting the market's growth. The World Health Organization report in March 2020 suggested using conservative fluid management in patients with SARS COVID-19 when there is no evidence of shock. Several clinical studies are ongoing for different intravenous drug solutions to treat COVID-19 patients. For instance, clinicaltrial.gov conducted a study in 2020 titled 'Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients (INVENT COVID)', by performing a randomized, double-blind, parallel-group, placebo-controlled, multi-center clinical study of intravenous imatinib in 90 mechanically-ventilated, adult subjects with COVID-19-related ARDS. This study is expected to be completed in 2022.
The major factor attributing to the market's growth is the increase in the prevalence of diseases, such as gastrointestinal diseases, neurological diseases, and cancer, where intravenous solutions are the main sources of energy for patients. According to the World Health Organization, diarrhea is the second leading cause of death in children under five years, with 370,000 deaths in 2019.
Product innovations, such as premixed solutions for better convenience and to reduce the amount of packaging waste, and the availability of solutions in portable packages, which becomes easier for the patients to use the drips in the comfort of their home rather than at a hospital, are few other factors boosting the market's growth. For instance, in June 2019, Eurolife Healthcare, a manufacturing and distribution company of specialty infusion and pharmaceuticals, launched intravenous IV products Discport and Lifeport, which reduce the chances of any infections and are easy to use.
However, regulatory and quality requirements contribute additional cost and complexity to the market. Intravenous fluids are regulated as pharmaceutical products and carry all the capital investment requirements of sterile injectable medications despite being sold at relatively low prices, hindering the market's growth.
Intravenous Solutions Industry Segmentation
As per the scope of the report, intravenous solutions are chemically prepared fluids administered in the body through the venous circulation to maintain or replace the level of lost body fluid. The intravenous solutions market is segmented by type, solution composition, and geography. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD million for the above segments.
| By Type | |
| Total Parenteral Nutrition | |
| Peripheral Parenteral Nutrition |
| By Solution Composition | |
| Saline | |
| Carbohydrates | |
| Vitamins and Minerals | |
| Other Solution Compositions |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Global Intravenous Solutions Market Size Summary
The intravenous solutions market is experiencing a positive trajectory, driven by the increasing prevalence of chronic diseases such as gastrointestinal, neurological disorders, and cancer. These conditions necessitate the use of intravenous solutions as a primary source of energy and nutrition for patients, particularly in intensive care settings. The market's growth has been further accelerated by the COVID-19 pandemic, which heightened the demand for IV solutions to manage patient care in ICUs and spurred research into IV-based treatments. Innovations in product offerings, such as premixed solutions and portable packages, are enhancing convenience and reducing waste, thereby attracting more consumers. However, the market faces challenges due to stringent regulatory and quality requirements, which add complexity and cost to the production of intravenous solutions.
The United States is poised to be a significant contributor to the market's expansion, driven by a high burden of chronic diseases, a rising number of preterm births, and an increasing frequency of surgeries. The geriatric population, which is more susceptible to chronic conditions, is also expected to drive demand for intravenous solutions. Major market players are investing in research and development to introduce new treatments, which is expected to further propel market growth. The competitive landscape is characterized by the presence of key players such as Ajinomoto, B. Braun Melsungen AG, Baxter International, Grifols, and ICU Medical Inc., who are actively engaging in strategic initiatives to enhance their market position.
Global Intravenous Solutions Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Diseases, such as Gastrointestinal Disorder, Neurological Diseases, and Cancer
-
1.2.2 Advancements and New Innovations in the Products for Patient Convenience
-
-
1.3 Market Restraints
-
1.3.1 Regulatory and Quality Requirements
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Type
-
2.1.1 Total Parenteral Nutrition
-
2.1.2 Peripheral Parenteral Nutrition
-
-
2.2 By Solution Composition
-
2.2.1 Saline
-
2.2.2 Carbohydrates
-
2.2.3 Vitamins and Minerals
-
2.2.4 Other Solution Compositions
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Global Intravenous Solutions Market Size FAQs
What is the current Global Intravenous Solutions Market size?
The Global Intravenous Solutions Market is projected to register a CAGR of 4.30% during the forecast period (2024-2029)
Who are the key players in Global Intravenous Solutions Market?
Ajinomoto, B. Braun Melsungen AG, Grifols, Baxter International and ICU Medical Inc. are the major companies operating in the Global Intravenous Solutions Market.
